Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Analytical Method Development: SOP for Preservative Efficacy in Eye Drops – V 2.0

Posted on By

Analytical Method Development: SOP for Preservative Efficacy in Eye Drops – V 2.0

Standard Operating Procedure for Preservative Efficacy Testing in Eye Drops in Analytical Method Development


Department Analytical Method Development
SOP No. SOP/AMD/249/2025
Supersedes SOP/AMD/249/2022
Page No. Page 1 of 13
Issue Date 21/05/2025
Effective Date 23/05/2025
Review Date 21/05/2026

1. Purpose

To define the procedure for conducting preservative efficacy testing (PET) in ophthalmic preparations (eye drops) to evaluate the effectiveness of antimicrobial preservatives in inhibiting

microbial growth over a defined period as per pharmacopeial standards.

2. Scope

This SOP applies to Analytical Method Development and Quality Control personnel performing preservative efficacy testing for eye drop formulations during formulation development, stability studies, and product release phases.

3. Responsibilities

  • Microbiologist: Performs inoculation, sampling, enumeration, and interpretation of results.
  • QC Analyst: Assists with dilutions, incubation, and data logging.
  • QA Executive: Reviews preservative efficacy test results and approves final report.

4. Accountability

The Head of Analytical Method Development is accountable for ensuring that PET is executed using validated methodology in accordance with USP <51> and EP 5.1.3.

5. Procedure

5.1 Microorganisms Used

Challenge the formulation with the following ATCC organisms:

  • Staphylococcus aureus (ATCC 6538)
  • Pseudomonas aeruginosa (ATCC 9027)
  • Escherichia coli (ATCC 8739)
  • Candida albicans (ATCC 10231)
  • Aspergillus brasiliensis (ATCC 16404)

5.2 Inoculum Preparation

  1. Grow each microorganism separately on suitable media (e.g., TSB, SDA) for 18–24 hours.
  2. Harvest cells in sterile saline and adjust turbidity to match 0.5 McFarland standard.
  3. Determine CFU count using plate count method to achieve a final challenge of 1×105 to 1×106 CFU/mL in the product.

5.3 Inoculation of Test Product

  1. Using aseptic technique, inoculate the eye drop formulation with each organism to achieve the desired CFU concentration.
  2. Mix well without compromising sterility.

5.4 Sampling Schedule

Collect 1 mL aliquots from each inoculated test unit at the following time intervals:

  • T = 0 (initial count)
  • Day 7
  • Day 14
  • Day 28

5.5 Enumeration of Microorganisms

  1. Perform serial dilution of each sample.
  2. Plate suitable dilutions on selective agar (e.g., MHA, SDA) and incubate:
    • Bacteria: 30–35°C for 3–5 days
    • Fungi: 20–25°C for 5–7 days
  3. Count colonies and express results in CFU/mL.

5.6 Acceptance Criteria (USP <51>)

  • Bacteria: ≥ 3 log10 reduction by Day 14 and no increase thereafter
  • Fungi: No increase from initial count at Day 14 and Day 28

5.7 Data Analysis and Interpretation

  1. Calculate log reduction from initial count (T=0) at each time point.
  2. Evaluate trends across all organisms and verify against pharmacopeial standards.
  3. If criteria not met, investigate formulation preservative system and repeat validation.

6. Abbreviations

  • PET: Preservative Efficacy Testing
  • CFU: Colony Forming Units
  • SDA: Sabouraud Dextrose Agar
  • USP: United States Pharmacopeia
  • EP: European Pharmacopoeia

7. Documents

  1. Preservative Efficacy Data Log – Annexure-1
  2. Inoculum Preparation Log – Annexure-2
  3. PET Validation Report – Annexure-3

8. References

  • USP <51>: Antimicrobial Effectiveness Testing
  • EP 5.1.3: Efficacy of Antimicrobial Preservation
  • ICH Q6A: Specifications – Test Procedures and Acceptance Criteria

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name Dr. Nisha Verma Ajay Kulkarni Sunita Reddy
Designation Microbiologist QA Reviewer Head – AMD
Department Analytical Method Development QA Analytical Method Development

11. Annexures

Annexure-1: Preservative Efficacy Data Log

Organism Day 0 (CFU/mL) Day 7 Day 14 Day 28 Log Reduction Status
S. aureus 1.0×105 1.2×102 <10 <10 ≥ 3.0 Pass

Annexure-2: Inoculum Preparation Log

Organism Medium Growth Time CFU/mL Adjusted Prepared By
C. albicans SDA 24 hrs 1.1×106 Microbiology Analyst

Annexure-3: PET Validation Report

Preservative efficacy testing performed on batch OPH-249 met the requirements of USP <51> with ≥ 3 log reduction in bacteria and no fungal growth by Day 28. Preservative system validated for product shelf life up to 24 months.

Revision History:

Revision Date Revision No. Details Reason Approved By
21/05/2025 2.0 Updated log reduction criteria and added EP reference Annual Review Sunita Reddy
10/04/2022 1.0 Initial SOP Release New SOP QA Head
See also  Analytical Method Development: SOP for Bridging Study Between Two Analytical Methods - V 2.0
Analytical Method Development V 2.0 Tags:Analytical Method Development SOP, SOP for analytical calculations, SOP for analytical documentation, SOP for analytical instrument calibration, SOP for analytical instrument qualification, SOP for analytical method change control, SOP for analytical method deviation handling, SOP for analytical method documentation practices, SOP for analytical method lifecycle management, SOP for analytical method optimization, SOP for analytical method risk assessment, SOP for analytical method training and competency, SOP for analytical method transfer protocol, SOP for analytical method validation, SOP for forced degradation studies, SOP for HPLC method development, SOP for limit of detection (LOD) determination, SOP for limit of quantitation (LOQ) determination, SOP for method accuracy testing, SOP for method linearity assessment, SOP for method precision evaluation, SOP for method reproducibility, SOP for method robustness testing, SOP for method transfer, SOP for method verification, SOP for qualification of working standards, SOP for reference standard handling, SOP for specificity testing in analytical methods, SOP for stability indicating methods, SOP for system suitability testing

Post navigation

Previous Post: Gel Manufacturing: SOP for Development of Cosmetic Gels – V 2.0
Next Post: Manufacturing: SOP for Conducting Microbial Monitoring during Filling Process – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version